Monday, January 15, 2018 -- Xavier Bosch, MD, discusses a second-generation vaccination against HPV for the prevention of cervical cancer.
Monday, January 08, 2018 -- This follows the extension of a QUT collaboration with Johnson & Johnson Innovation, Janssen Vaccines & Prevention, and Janssen Cilag Pty Ltd.
Tuesday, January 16, 2018 -- Purpose: As previously reported, treatment of high-grade cervical dysplasia with VGX-3100 resulted in complete histopathologic regression (CR) concomitant with elimination of HPV16/18 infection in 40.0% of VGX-3100–treated patients compared with only 14.3% in placebo recipients in a randomized phase IIb study. Here, we identify clinical and immunologic characteristics that either predicted or correlated with therapeutic benefit from VGX-3100 to identify parameters that might guide clinical decision-making for this disease. Experimental Design: We analyzed samples taken from cervical swabs, whole blood, and tissue biopsies/resections to determine correlates and predictors of treatment success. Results: At study entry, the presence of preexisting immunosuppressive factors such as FoxP3 and PD-L1 in cervical lesions showed no association with treatment outcome. The combination of HPV
Friday, January 12, 2018 -- Cutaneous beta human papillomavirus (HPV) types are suspected to be involved, together with ultraviolet (UV) radiation, in the development of non-melanoma skin cancer, the most common form of human cancer. A new study by researchers from the International Agency for Research on Cancer (IARC) and the German Cancer Research Center (DKFZ), published today in PLoS Pathogens, used a transgenic mouse model in which the expression of beta HPV38 oncogenes can be modulated in the skin. Their findings support the concept that beta HPV types act only at an initial stage of carcinogenesis, by potentiating the deleterious effects of UV radiation. Viarisio D, Muller-Decker K, Accardi R, Robitaille A, Durst M, Beer K, et al. Beta HPV38 oncoproteins act with
Thursday, January 11, 2018 -- by Joseph G. Skeate, Diane M. Da Silva, Elena Chavez-Juan, Snjezana Anand, Richard Nuccitelli, W. Martin Kast Nano-Pulse Stimulation (NPS) is a non-thermal pulsed electric field modality that has been shown to have cancer therapeutic effects. Here we applied NPS treatment to the human papillomavirus type 16 (HPV 16)-transformed C3.43 mouse tumor cell model and showed that it is effective at eliminating primary tumors through the induction of immunogenic cell death while subsequently increasing the number of tumor-infiltrating lymphocytes within the tumor microenvironment. In vitro NPS treatment of C3.43 cells resulted in a doubling of activated caspase 3/7 along with the translocation of phosphatidylserine (PS) to the outer leaflet of the plasma membrane, indicating programmed cell death activity. Tumor-bearing
Wednesday, January 03, 2018 -- The more dental health professionals know about human papillomvavirus prevention activities, such as the HPV vaccine, the better suited they are to be a "line of protection against HPV and cancer," according to research published in the January issue of The Journal of the American Dental Association.
Monday, January 15, 2018 -- Seeing upwards of 85% of children in the United States each year, dentists are key to promoting HPV prevention methods, but more training and education is needed first.
Wednesday, December 27, 2017 -- For patients with stage III disease, intensification to triple-modality therapy may improve survival
Thursday, January 11, 2018 -- Certain head and neck cancers that are positive for high-risk types of human papillomavirus (HPV) have a better prognosis and may need less aggressive treatment.